UA126821C2 - Похідні кавової кислоти і їх застосування - Google Patents
Похідні кавової кислоти і їх застосування Download PDFInfo
- Publication number
- UA126821C2 UA126821C2 UAA202003449A UAA202003449A UA126821C2 UA 126821 C2 UA126821 C2 UA 126821C2 UA A202003449 A UAA202003449 A UA A202003449A UA A202003449 A UAA202003449 A UA A202003449A UA 126821 C2 UA126821 C2 UA 126821C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- compound according
- cancer
- compounds
- carbon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584591P | 2017-11-10 | 2017-11-10 | |
| PCT/US2018/059975 WO2019094689A1 (en) | 2017-11-10 | 2018-11-09 | Caffeic acid derivatives for treating hyperproliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA126821C2 true UA126821C2 (uk) | 2023-02-08 |
Family
ID=64664389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202003449A UA126821C2 (uk) | 2017-11-10 | 2018-11-09 | Похідні кавової кислоти і їх застосування |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10703721B2 (https=) |
| EP (1) | EP3707125A1 (https=) |
| JP (1) | JP7428642B2 (https=) |
| KR (1) | KR20200085815A (https=) |
| CN (1) | CN111417625A (https=) |
| AU (1) | AU2018366270B2 (https=) |
| BR (1) | BR112020009219A2 (https=) |
| CA (1) | CA3081975A1 (https=) |
| EA (1) | EA202091164A1 (https=) |
| MX (1) | MX2020004871A (https=) |
| SG (1) | SG11202004230XA (https=) |
| TW (1) | TWI846678B (https=) |
| UA (1) | UA126821C2 (https=) |
| WO (1) | WO2019094689A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12539503B2 (en) | 2022-08-03 | 2026-02-03 | The University Of Toledo | Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| PT1701941E (pt) | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| BRPI0709916B8 (pt) | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| NZ590372A (en) * | 2008-07-08 | 2012-09-28 | Univ Texas | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| EP2619184B1 (en) | 2010-09-24 | 2018-05-23 | The Regents of the University of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| US9868736B2 (en) | 2013-10-10 | 2018-01-16 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| WO2015183987A1 (en) | 2014-05-27 | 2015-12-03 | Pharmakea, Inc. | Compositions and methods of delivery of deubiquitinase inhibitors |
| CA2948883A1 (en) * | 2014-06-02 | 2015-12-10 | Pharmakea, Inc. | Deubiquitinase inhibitors |
-
2018
- 2018-11-08 TW TW107139731A patent/TWI846678B/zh active
- 2018-11-09 KR KR1020207015972A patent/KR20200085815A/ko not_active Ceased
- 2018-11-09 US US16/185,669 patent/US10703721B2/en active Active
- 2018-11-09 EP EP18816306.7A patent/EP3707125A1/en active Pending
- 2018-11-09 JP JP2020525946A patent/JP7428642B2/ja active Active
- 2018-11-09 MX MX2020004871A patent/MX2020004871A/es unknown
- 2018-11-09 CA CA3081975A patent/CA3081975A1/en active Pending
- 2018-11-09 EA EA202091164A patent/EA202091164A1/ru unknown
- 2018-11-09 WO PCT/US2018/059975 patent/WO2019094689A1/en not_active Ceased
- 2018-11-09 UA UAA202003449A patent/UA126821C2/uk unknown
- 2018-11-09 SG SG11202004230XA patent/SG11202004230XA/en unknown
- 2018-11-09 AU AU2018366270A patent/AU2018366270B2/en not_active Ceased
- 2018-11-09 CN CN201880077894.0A patent/CN111417625A/zh active Pending
- 2018-11-09 BR BR112020009219-3A patent/BR112020009219A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019094689A1 (en) | 2019-05-16 |
| MX2020004871A (es) | 2020-08-06 |
| EP3707125A1 (en) | 2020-09-16 |
| JP2021502374A (ja) | 2021-01-28 |
| TWI846678B (zh) | 2024-07-01 |
| CN111417625A (zh) | 2020-07-14 |
| AU2018366270A1 (en) | 2020-05-21 |
| KR20200085815A (ko) | 2020-07-15 |
| CA3081975A1 (en) | 2019-05-16 |
| AU2018366270B2 (en) | 2023-04-20 |
| TW201922707A (zh) | 2019-06-16 |
| US20190177276A1 (en) | 2019-06-13 |
| JP7428642B2 (ja) | 2024-02-06 |
| SG11202004230XA (en) | 2020-06-29 |
| BR112020009219A2 (pt) | 2020-10-20 |
| EA202091164A1 (ru) | 2020-08-03 |
| US10703721B2 (en) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11708319B2 (en) | Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers | |
| DE60007347T2 (de) | Isoxazolcarboxamid-derivate als antagonisten des alpha1-adrenergischen rezeptors | |
| Aytemir et al. | Anticonvulsant and neurotoxicity evaluation of some novel kojic acids and allomaltol derivatives | |
| WO2019227040A1 (en) | Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases | |
| KR20110136888A (ko) | 퀴녹살린 유도체 및 양성 및 악성 종양 질병 치료를 위한 이의 용도 | |
| UA126821C2 (uk) | Похідні кавової кислоти і їх застосування | |
| CN117229146B (zh) | 一种咖啡酸苯乙酯衍生物及其制备方法与用途 | |
| WO2017223514A1 (en) | Lxr inverse agonists for treatment of cancer | |
| CN107216283A (zh) | 一种含有二氢吡啶结构的β－榄香烯衍生物及其制备方法和用途 | |
| JP6807941B2 (ja) | スルファメート誘導体化合物、その製造方法および用途 | |
| WO2017035733A1 (zh) | 美金刚与牛蒡子苷元的缀合物及其组合物和用途 | |
| JP2025536344A (ja) | ｓＧＣ刺激剤でのミトコンドリア疾患の処置 | |
| KR101457637B1 (ko) | 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물 | |
| CN114853630A (zh) | 一种2,6-二苯亚甲基环己酮肟类化合物及其制备方法和应用 | |
| CN113105409A (zh) | 2-(羟基苄基)苯并[d]异噻唑酮类化合物、其制备方法和用途 | |
| DE60005368T2 (de) | Thienopyran-carboxamid-derivate | |
| WO2025252064A1 (en) | Thr-beta modulator for treatment of metabolic diseases | |
| CN109678736B (zh) | 查尔酮曼尼希碱类化合物、其制备方法和用途 | |
| KR20250045262A (ko) | 신규 페닐프로파노이드 유도체 화합물을 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 조성물 | |
| CN121318765A (zh) | 一种抗肿瘤咖啡酸苯乙酯衍生物及其制备方法与用途 | |
| CN120192295A (zh) | 一种芳基丙胺类衍生物及其应用 | |
| CN121378212A (zh) | 2-(哌啶烷基)哒嗪酮类化合物及其制备方法和用途 | |
| JP2023549962A (ja) | Ｐｕ．１阻害剤としての化合物 | |
| KR20180125090A (ko) | 신규 아세틸콜린에스터라제 저해 유도체, 이의 제조방법, 및 이를 유효성분으로 함유하는 신경계 질환의 예방 또는 치료용 약학적 조성물 | |
| BR112016029672B1 (pt) | Composto bifenil amida com grupos éter modificados como inibidores de hsp90 e indutores de hsp70, composição farmacêutica que compreende o dito composto, bem como uso terapêutico do mesmo |